About RXi Pharmaceuticals Corporation (NASDAQ:RXII)
RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company's development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:RXII
- CUSIP: N/A
- Web: www.rxipharma.com
- Market Cap: $13.49 million
- Outstanding Shares: 23,247,000
- 50 Day Moving Avg: $0.52
- 200 Day Moving Avg: $0.59
- 52 Week Range: $0.32 - $2.93
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.02
- P/E Growth: 0.0000
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.26 per share
- Price / Book: 2.28
- EBITDA: ($9,400,000.00)
- Return on Equity: -155.48%
- Return on Assets: -102.55%
- Current Ratio: 3.30%
- Quick Ratio: 3.30%
- Average Volume: 355,080 shs.
- Beta: 1.24
- Short Ratio: 7.01
Frequently Asked Questions for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
What is RXi Pharmaceuticals Corporation's stock symbol?
RXi Pharmaceuticals Corporation trades on the NASDAQ under the ticker symbol "RXII."
How were RXi Pharmaceuticals Corporation's earnings last quarter?
RXi Pharmaceuticals Corporation (NASDAQ:RXII) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.11) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.11). During the same period in the previous year, the company earned ($0.34) EPS. View RXi Pharmaceuticals Corporation's Earnings History.
When will RXi Pharmaceuticals Corporation make its next earnings announcement?
Where is RXi Pharmaceuticals Corporation's stock going? Where will RXi Pharmaceuticals Corporation's stock price be in 2017?
0 brokerages have issued 1-year target prices for RXi Pharmaceuticals Corporation's shares. Their forecasts range from $1.71 to $1.71. On average, they anticipate RXi Pharmaceuticals Corporation's share price to reach $1.71 in the next year. View Analyst Ratings for RXi Pharmaceuticals Corporation.
Who are some of RXi Pharmaceuticals Corporation's key competitors?
Some companies that are related to RXi Pharmaceuticals Corporation include OncoSec Medical Incorporated (ONCS), Burcon NutraScience Corp (BUR), Repros Therapeutics (RPRX), OpGen (OPGN), Senestech (SNES), Oxford Pharmascience Group Plc (OXP), Novogen Limited (NVGN), Transgenomic (PRPO), Jaguar Animal Health (JAGX), Metabolix (YTEN), Ampliphi Biosciences Corp (APHB), Synairgen plc (SNG), Ixico Plc (IXI), Roka Bioscience (ROKA), Akers Biosciences (AKR), OncoGenex Pharmaceuticals (ACHV), Rosetta Genomics (ROSG) and Anacor Pharmaceuticals (ANAC).
Who are RXi Pharmaceuticals Corporation's key executives?
RXi Pharmaceuticals Corporation's management team includes the folowing people:
- Robert J. Bitterman, Independence Chairman of the Board
- Geert Cauwenbergh Ph.D., President, Chief Executive Officer, acting Chief Financial Officer, Director
- Gerrit Dispersyn, Chief Development Officer
- Keith L. Brownlie CPA, Independent Director
- H. Paul Dorman, Independent Director
- Jonathan E Freeman Ph.D., Independent Director
- Curtis A. Lockshin Ph.D., Independent Director
How do I buy RXi Pharmaceuticals Corporation stock?
Shares of RXi Pharmaceuticals Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is RXi Pharmaceuticals Corporation's stock price today?
MarketBeat Community Rating for RXi Pharmaceuticals Corporation (NASDAQ RXII)MarketBeat's community ratings are surveys of what our community members think about RXi Pharmaceuticals Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of RXi Pharmaceuticals Corporation stock can currently be purchased for approximately $0.58.
Consensus Ratings for RXi Pharmaceuticals Corporation (NASDAQ:RXII) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||$1.71 (194.62% upside)|Consensus Price Target History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Analysts' Ratings History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/21/2016||S&P Equity Research||Lower Price Target||$2.35 -> $1.71||N/A|
|6/7/2016||HC Wainwright||Initiated Coverage||Buy||$3.50||N/A|
Earnings History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)Earnings History by Quarter for RXi Pharmaceuticals Corporation (NASDAQ RXII)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/13/2016||Q116||($0.45)||($0.34)||$34.00 million||$10.00 million||View||Listen|
|5/13/2015||Q115||($0.10)||($0.13)||$0.02 million||$0.03 million||View||Listen|
|3/30/2015||Q414||($0.14)||($0.13)||$0.02 million||$0.01 million||View||N/A|
|5/14/2014||Q114||($0.31)||($0.32)||$0.08 million||$0.03 million||View||N/A|
Earnings Estimates for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
2017 EPS Consensus Estimate: ($0.74)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Insider Ownership Percentage: 5.71%Insider Trades by Quarter for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Institutional Ownership Percentage: 1.67%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/2/2017||Geert Cauwenbergh||CEO||Buy||10,000||$0.45||$4,500.00|| |
|9/7/2017||Alexey Eliseev||Insider||Sell||176,800||$0.54||$95,472.00|| |
|9/1/2017||Alexey Eliseev||Insider||Sell||23,200||$0.57||$13,224.00|| |
|8/24/2017||Geert Cauwenbergh||CEO||Buy||10,000||$0.55||$5,500.00|| |
|6/23/2017||Gerrit Dispersyn||Insider||Buy||3,500||$0.62||$2,170.00|| |
|6/22/2017||Geert Cauwenbergh||CEO||Buy||10,000||$0.63||$6,300.00|| |
|4/26/2017||Geert Cauwenbergh||CEO||Buy||10,000||$0.65||$6,500.00|| |
|3/17/2017||Geert Cauwenbergh||CEO||Buy||10,000||$0.77||$7,700.00|| |
|2/17/2017||Geert Cauwenbergh||CEO||Buy||10,000||$0.69||$6,900.00|| |
|2/8/2017||Geert Cauwenbergh||CEO||Buy||10,000||$0.69||$6,900.00|| |
|1/25/2017||Geert Cauwenbergh||CEO||Buy||10,000||$0.70||$7,000.00|| |
|1/19/2017||Geert Cauwenbergh||CEO||Buy||10,000||$0.69||$6,900.00|| |
|4/2/2015||Geert Cauwenbergh||CEO||Buy||5,000||$0.72||$3,600.00|| |
|2/17/2015||Geert Cauwenbergh||CEO||Buy||4,000||$1.17||$4,680.00|| |
|2/10/2015||Geert Cauwenbergh||CEO||Buy||2,000||$1.24||$2,480.00|| |
|1/22/2015||Robert J Bitterman||Director||Buy||5,000||$1.20||$6,000.00|| |
|1/20/2015||Geert Cauwenbergh||CEO||Buy||10,000||$1.03||$10,300.00|| |
|12/30/2014||Geert Cauwenbergh||CEO||Buy||2,500||$1.59||$3,975.00|| |
|10/13/2014||Geert Cauwenbergh||CEO||Buy||3,000||$1.68||$5,040.00|| |
|9/19/2014||Geert Cauwenbergh||CEO||Buy||4,500||$2.20||$9,900.00|| |
|9/16/2014||Geert Cauwenbergh||CEO||Buy||5,000||$2.08||$10,400.00|| |
|9/15/2014||Geert Cauwenbergh||CEO||Buy||10,000||$2.18||$21,800.00|| |
|7/15/2014||Geert Cauwenbergh||CEO||Buy||1,000||$2.50||$2,500.00|| |
|7/9/2014||Geert Cauwenbergh||CEO||Buy||1,400||$2.57||$3,598.00|| |
|7/2/2014||Geert Cauwenbergh||CEO||Buy||2,000||$2.86||$5,720.00|| |
|6/19/2014||Geert Cauwenbergh||CEO||Buy||2,000||$2.98||$5,960.00|| |
|6/9/2014||Geert Cauwenbergh||CEO||Buy||1,000||$3.05||$3,050.00|| |
|6/4/2014||Geert Cauwenbergh||CEO||Buy||2,000||$2.94||$5,880.00|| |
|10/31/2013||Geert Cauwenbergh||CEO||Buy||1,000||$3.17||$3,170.00|| |
|10/23/2013||Geert Cauwenbergh||CEO||Buy||1,000||$3.34||$3,340.00|| |
|10/9/2013||Geert Cauwenbergh||CEO||Buy||1,000||$3.15||$3,150.00|| |
|8/29/2013||Curtis Lockshin||Director||Buy||1,000||$3.70||$3,700.00|| |
Headline Trends for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Latest Headlines for RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Loading headlines, please wait.
RXi Pharmaceuticals Corporation (RXII) Chart for Sunday, October, 22, 2017